Icatibant

Therapeutic

Approved for treatment of hereditary angioedema in EU; orphan drug in USA

Structural features

SMILES

[H][C@]12C[C@]([H])(N(C(=O)[C@@]3([H])CC4=C(CN3C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)[C@]3([H])C[C@@H](O)CN3C(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C=CC=C4)[C@@]1([H])CCCC2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O

Sequence

rRPXGXSXR

Molar mass

1304.54 g/mol

Constitutional members:

10

Natural amino acids

5

D-Amino acids

2

N-terminus

H

C-terminus

COOH

Cyclic

no

Members/cycle

N.A.

Bond to form cycle

N.A.

Lipidation

no

Glycosylation

no

Route of administration

SC

Terminal half-life

1-2 hours

Protein binding

-

Absorption and Bioavailability

0.97

References